PROFILPELAJAR.COM

CU-13001

CU-13001
Clinical data
Other namesCU13001
Routes of
administration		Oral[1]
Drug classALOX15 inhibitor
ATC code
  • None

CU-13001 is a 15-lipoxygenase (15-LOX, ALOX15) inhibitor which is under development for the treatment of Parkinson's disease.[1][2][3][4][5] It is taken orally.[1] It is thought that 4-hydroxynonenal (4-HNE), a product of 15-LOX, may be involved in the etiology of Parkinson's disease, and that by inhibiting 4-HNE formation, CU-13001 theoretically may be able to prevent or slow the progression of Parkinson's disease.[3][4] The drug is under development by Acurex Biosciences.[1][2][4] As of September 2024, it is in the preclinical research stage of development for Parkinson's disease.[1][2][5][4] The chemical structure of CU-13001 does not yet appear to have been disclosed.[1]

See also

References

  1. ^ a b c d e f "CU 13001". AdisInsight. 28 September 2024. Retrieved 1 June 2026.
  2. ^ a b c "Delving into the Latest Updates on CU-13001 with Synapse". Synapse. 30 May 2026. Retrieved 1 June 2026.
  3. ^ a b Fanning S, Selkoe D (November 2025). "Parkinson disease is a fatty acidopathy". Nature Reviews. Neurology. 21 (11): 642–655. doi:10.1038/s41582-025-01142-2. PMC 13092291. PMID 41034503. The biological effects of some PUFAs might be elicited through their oxidation products, for example, oxylipins55. Targeting of such signalling molecules and byproducts of fatty acid metabolism might have therapeutic promise. One example under consideration in preclinical studies is reduction of a PUFA peroxidation product, 4-hydroxynonenal (4-HNE), using an inhibitor (CU-13001) of 15-lipoxygenase (15- LO).
  4. ^ a b c d Parkinson's UK (7 August 2024). "Parkinson's UK invests in developing potential new drug with Acurex Biosciences". Parkinson's UK. Parkinson's UK. Retrieved 1 June 2026.
  5. ^ a b "Preclinical Efficacy Studies for CU-13001, a 15-Lipoxygenase Inhibitor for the Treatment of Parkinson's Disease". The Michael J. Fox Foundation for Parkinson's Research. Retrieved 1 June 2026.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.